Traditional Chinese medicine enables the development of small-molecule inhibitors of HSP47,future therapeutic implication in venous thromboembolism  

作　　者：LI Yuan YAO Li 

机构地区：[1]Department of Medicinal Chemistry and Natural Medicine Chemistry,Department of Pharmacognosy,College of Pharmacy,Harbin Medical University,Harbin 150081,China

出　　处：《Chinese Journal of Natural Medicines》2023年第9期641-642,共2页中国天然药物（英文版）

基　　金：the Natural Science Foundation of Heilongjiang Province(No.LH2021H016);the Fundamental Research Funds for the Central Universities(No.KLSB2022KF-02);HMU Marshal Initiative Funding(No.HMUMIF-21026).

摘　　要：Venous thromboembolism(VTE)is a typical cardiovascular disease,which is phenotypically characterized by painful leg swelling,chest pain,shortness of breath,and even death[1].VTE renders a high morbidity and mortality as it is the main cause of death of hospitalized patients.Clinical treatment of VTE mostly adopts immediate anticoagulation agents via a risk assessment of bleeding.Basically,traditional Chinese medicine(TCM)has unique medicinal priority on reducing swelling,stopping bleeding and promoting blood circulation,which therefore can eliminate the obstruction of patient’s channels so as to exert analgesic and anti-inflammatory bioactivities[2].However,well-controlled and-designed clinical trials of the selected TCM formulae are widely performed to support the clinical application of traditional Chinese medicine for the prevention of VTE in a real world.

关 键 词：PREVENTION SWELLING enable 

分 类 号：R965[医药卫生—药理学]